During 2018 Q3 the big money sentiment increased to 1.07. That’s change of 0.02, from 2018Q2’s 1.05. 19 investors sold all, 107 reduced holdings as Bio-Rad Laboratories, Inc. ratio is positive. 83 grew positions while 52 funds amassed positions. Funds hold 17.73 million shares thus 2.92% less from 2018Q2’s 18.26 million shares.
Pub Employees Retirement Systems Of Ohio accumulated 16,313 shs. 224 were accumulated by Prelude Cap Management Ltd. Grantham Mayo Van Otterloo And invested 0% of its capital in Bio-Rad Laboratories, Inc. (NYSE:BIO). Georgia-based Voya Mgmt has invested 0% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Centurylink Mngmt accumulated 3,680 shs or 0.41% of the stock. 170 are held by Trustmark Bancorp Trust Department. Vanguard Grp Inc has invested 0.02% of its capital in Bio-Rad Laboratories, Inc. (NYSE:BIO). Minnesota-based Ameriprise Fincl Inc has invested 0.01% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Jpmorgan Chase & holds 43,857 shs. State Of Wisconsin Board invested in 0% or 4,055 shs. Teacher Retirement Systems Of Texas has 2,470 shs for 0.01% of their capital. Assetmark has 24 shs for 0% of their capital. Asset Mgmt One Co Limited accumulated 0% or 6,491 shs. 17,538 were accumulated by Hsbc Public Limited Company. Commercial Bank Of Mellon invested in 231,356 shs.
Bio-Rad Laboratories, Inc. registered $1.27 million net activity with 0 insider buys and 4 sales since December 11, 2018. STARK JAMES R sold $216,045 worth of Bio-Rad Laboratories, Inc. (NYSE:BIO) or 848 shs on Wednesday, December 12. TSINGOS CHRISTINE A sold 1,411 shs worth $349,928. The insider TUMOLO ANNETTE sold 2,376 shs worth $604,704.
Earnings report for Bio-Rad Laboratories, Inc. (NYSE:BIO) is anticipated on February, 26., according to Zacks. Analysts predict $1.75 EPS. That’s $0.25 up or 16.67 % from 2018’s earnings of $1.5. If $1.75 is reported, BIO’s profit will hit $52.05 million for 38.32 P/E. After $0.91 EPS was announced last quarter, analysts now see EPS growth of 92.31 % for Bio-Rad Laboratories, Inc.. BIO is touching $268.22 during the last trading session, after decreased 0.78%.Currently Bio-Rad Laboratories, Inc. is downtrending after 1.28% change in last February 19, 2018. BIO has also 9,687 shares volume. The stock underperformed the S&P 500 by 1.28%.
Bio-Rad Laboratories, Inc. (NYSE:BIO) Ratings Coverage
In total 3 analysts cover Bio-Rad Laboratories (NYSE:BIO). “Buy” rating has 2, “Sell” are 0, while 1 are “Hold”. (NYSE:BIO) has 67% bullish analysts. 5 are the (NYSE:BIO)’s ratings reports on Feb 19, 2019 according to StockzIntelligence Inc. In Friday, November 2 report Barclays Capital maintained the stock with “Equal-Weight” rating. In Thursday, January 3 report Barclays Capital upgraded the stock to “Overweight” rating.
Bio-Rad Laboratories, Inc. manufactures and supplies products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components for life science research, healthcare, analytical chemistry, and other markets.The company has $7.98 billion market cap. The firm operates through two divisions, Life Science and Clinical Diagnostics.The P/E ratio is 6.35. The Life Science segment develops, makes, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.
For more Bio-Rad Laboratories, Inc. (NYSE:BIO) news published recently go to: Seekingalpha.com, Benzinga.com, Businesswire.com, or Seekingalpha.com. The titles are as follows: “Bio-Rad Laboratories (BIO) Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” published on August 07, 2018, “25 Stocks Moving In Tuesday’s Pre-Market Session – Benzinga” on February 19, 2019, “Christine Tsingos Announces Plans to Retire as CFO of Bio-Rad Laboratories, Inc. Effective April 30, 2019 – Business Wire” with a publish date: January 03, 2019, “The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial – Yahoo! Finance News” and the last “Bio-Rad Technologies: A Definite Avoid – Seeking Alpha” with publication date: September 07, 2017.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.